Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kine Sciences Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This single action represents the company's current active pursuit of patent protection for its pharmaceutical innovations.
The prosecution process is centralized, involving 1 distinct examiner and 1 distinct art unit. This concentration indicates that the technical scope of the filings falls under a single regulatory department. This simplifies the prosecution strategy by focusing on the standards of one specific art unit.
KATAKAM, SUDHAKAR is the busiest examiner, holding 1 busiest examiner pending office action. This examiner is responsible for the only active matter in the portfolio. The immediate future of the company's patent rights is tied to the review and decisions of this specific examiner.
The presence of 1 distinct examiner for 1 pending office action ensures a direct relationship between the examiner and the workload. This consistency may lead to more predictable prosecution timelines. Practitioners can focus their efforts on the specific requirements of KATAKAM, SUDHAKAR within the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174730 | USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES | KATAKAM, SUDHAKAR | 20d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18174730 | USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | 20d | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial